Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Arpraziquantel→

Arpraziquantel Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
57452-98-9
Molecular formula
C19H24N2O2
Molecular weight
312.4 g/mol
Drug class
Praziquantel enantiomerantischistosomal and cestocidal anthelmintic
Mechanism of action
Increases parasite membrane permeability to calcium ions, causing rapid muscle contraction, paralysis and tegumental damage, facilitating immune-mediated parasite clearance.
Indications / reported uses
  • Treatment of schistosomiasis caused by susceptible Schistosoma species in children aged 3 months to 6 years under the paediatric arpraziquantel product authorisation; use is specific to the dispersible paediatric formulation

Sources: WHO — Arpraziquantel paediatric formulation information · PubMed — Arpraziquantel paediatric schistosomiasis · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Arpraziquantel Environmental Risk Assessment (ERA) (the Arpraziquantel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.